Vial, a San Francisco, CA-based Contract Research Organization (CRO), raised $67M in Series B funding.
The round was led by General Catalyst with participation from Byers Capital, and BoxGroup.
The company intends to use the funds to accelerate the clinical development of medicines.
Led by CEO Simon Burns, Vial is a tech-enabled CRO that aims to make efficient trials through its technology platform that powers trials end-to-end from site startup to database lock. The platform is made up of three key platforms: Site Startup platform, eSource platform and Patient Recruiting platform. The company operates across multiple therapeutic areas (Dermatology CRO, Ophthalmology CRO, Oncology CRO, Gastroenterology CRO, Neurology CRO, and Cardiology CRO).
Vial has over 125 employees.
FinSMEs
30/11/2022